1-20 of 29
Afshin Dowlati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT155: Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer

Free
Afshin Dowlati, Alexander Spira, Xiaodong Shen, Yinjia Fu, Yiyuan Pan, Linda Liu, Renke Zhou, Yi-Long Wu
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT155.
https://doi.org/10.1158/1538-7445.AM2024-CT155
Published: 05 April 2024
View articletitled, Abstract CT155: Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer
Journal Articles

Abstract CT061: Pharmacodynamic analysis from a phase 1/2 study of subasumstat (TAK-981) as single agent in patients (pts) with advanced/refractory metastatic solid tumors

Free
Dina Stroopinsky, Slawomir Mandzuik, Daniel Anderson, José-Ángel Hernández-Rivas, Hadeel Assad, Allison Berger, Aleksander Chudnovsky, Qi Dong, Afshin Dowlati, Dejan Juric, Razelle Kurzrock, Iwona Lugowska, Kelly Richter, Jordi Rodón, David Schröder, Siddha Kasar, Anthony Olzanski
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT061.
https://doi.org/10.1158/1538-7445.AM2024-CT061
Published: 05 April 2024
View articletitled, Abstract CT061: Pharmacodynamic analysis from a phase 1/2 study of subasumstat (TAK-981) as single agent in patients (pts) with advanced/refractory metastatic solid tumors
Journal Articles

Abstract CT132: Trial in progress: A phase 1/2 study of ASP1570, a novel inhibitor of DGKζ, in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies

Free
Manish R. Patel, David J. Park, Stefano Tarantolo, Afshin Dowlati, Daniel Olson, Yuichiro Kaneko, Mei Tang, Serguei Soukharev, Masaomi Takizawa, Yohei Okada, Christine Fredericks, Teresa Flegel, Tsubasa Watanabe, Sue Lee, Jason John Luke
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT132.
https://doi.org/10.1158/1538-7445.AM2023-CT132
Published: 14 April 2023
View articletitled, Abstract CT132: Trial in progress: A phase 1/2 study of ASP1570, a novel inhibitor of DGKζ, in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies
Journal Articles

Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors

Free
Tian Zhang, Thomas Weart, Matthias Weiss, Drew Murray, Minaxi Jhawer, Edward Huynh, Shumei Kato, Amy Cummings, Lydia Usha, Arvinder Bhinder, Rajiv Desai, Brad Johnson, Anjali Avadhani, Cecile Rose T. Vibat, Lauren Lopez, Brynna Driscoll, Annajane Ward, Christie K. Rice, Blathnaid Donovan, Scott Sherrin, Mykel Robble, Stephanie O'Leary, Kimberly Blackwell, Amine Aziez, Stephanie Petrone, Kathleen Harnden, Kimberly Strickland, Sonya Reid, Mark Robson, Andrew S. Paulson, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT055.
https://doi.org/10.1158/1538-7445.AM2023-CT055
Published: 14 April 2023
View articletitled, Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors
Journal Articles

Abstract CT253: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies

Free
Thomas R. Evans, Afshin Dowlati, Juanita S. Lopez, Mohammed M. Milhem, Jordi Rodón Ahnert, Alexander Spira, Richard D. Carvajal, Matthew Zibelman, Sebastien J. Hazard, Amy Dickson, Lei Xu, Heather Cohen, Justin Bader, Kristen Hurov, Rajiv Sharma, Dominic Smethurst, Kyriakos P. Papadopoulos
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT253.
https://doi.org/10.1158/1538-7445.AM2023-CT253
Published: 14 April 2023
View articletitled, Abstract CT253: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies
Journal Articles

Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations

Free
David S. Hong, Afshin Dowlati, Howard Burris, Edward Chu, Marcia S. Brose, Anna F. Farago, Cornelis M. van Tilburg, Shivaani Kummar, Leo Mascarenhas, John A. Reeves, Marion Rudolph, Patricia Maeda, Barrett H. Childs, Theodore W. Laetsch, Alexander Drilon
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT062.
https://doi.org/10.1158/1538-7445.AM2020-CT062
Published: 15 August 2020
View articletitled, Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations
Journal Articles

Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer

Free
David Balli, Xuya Wang, Naiyer A. Rizvi, Timothy A. Chan, Afshin Dowlati, Parul Doshi, Han Chang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2047.
https://doi.org/10.1158/1538-7445.AM2020-2047
Published: 15 August 2020
View articletitled, Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer
Journal Articles

Abstract 2495: RUNX1T1 is amplified in combined small cell lung cancer

Free
Tian He, Karen McColl, Alyssa Savadelis, Yanwen Chen, Gary Wildey, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2495.
https://doi.org/10.1158/1538-7445.AM2018-2495
Published: 01 July 2018
View articletitled, Abstract 2495: RUNX1T1 is amplified in combined small cell lung cancer
Journal Articles

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Free
Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, Afshin Dowlati, George R. Stark
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (9): 2396–2406.
https://doi.org/10.1158/0008-5472.CAN-17-1920
Published: 30 April 2018
View articletitled, The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells
Open the PDF for The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells in another window
Includes: Supplementary data
Journal Articles

Abstract 2026: CHK1 inhibition synergizes with cisplatin to promote mitotic cell death via activation of caspase 2 and downregulation of E2F1 in small cell lung cancer

Free
Wei-Hsun Hsu, Xiaoliang Zhao, In-Gyu Kim, Guanhua Rao, Justine McCutcheon, Shuo-Tse Hsu, Afshin Dowlati, Yu-Wen Zhang, Giuseppe Giaccone
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2026.
https://doi.org/10.1158/1538-7445.AM2017-2026
Published: 01 July 2017
View articletitled, Abstract 2026: CHK1 inhibition synergizes with cisplatin to promote mitotic cell death via activation of caspase 2 and downregulation of E2F1 in small cell lung cancer
Journal Articles

Abstract 4490: Post-transcriptional regulation on PIAS3 expression in malignant mesothelioma

Free
Tian He, Karen McColl, Nneha Sakre, Gary Wildey, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4490.
https://doi.org/10.1158/1538-7445.AM2017-4490
Published: 01 July 2017
View articletitled, Abstract 4490: Post-transcriptional regulation on PIAS3 expression in malignant mesothelioma
Journal Articles

Abstract 2266: Molecular and genomic characterization of SCLC

Free
Stephen V. Liu, Edward S. Kim, Rebecca A. Feldman, Zoran Gatalica, Jeffrey Swensen, Hossein Borghaei, Alexander I. Spira, Gerold Bepler, Sandeep Reddy, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2266.
https://doi.org/10.1158/1538-7445.AM2016-2266
Published: 15 July 2016
View articletitled, Abstract 2266: Molecular and genomic characterization of SCLC
Journal Articles

Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma

Free
Neelesh Sharma, Josephine Dermawan, Andrei Purmal, Daniel Lindner, Gary Wildey, Afshin Dowlati, Andrei Gudkov, Katerina Gurova, George R. Stark
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3036.
https://doi.org/10.1158/1538-7445.AM2016-3036
Published: 15 July 2016
View articletitled, Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma
Journal Articles

Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

Free
David S. Hong, Anna F. Farago, Marcia S. Brose, Howard A. Burris, Afshin Dowlati, Todd M. Bauer, Matthew Taylor, Alice T. Shaw, Adriana Estrada-Bernal, Anh T. Lee, Nisha Nanda, Michael C. Cox, Robert C. Doebele
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2016-CT008
Published: 15 July 2016
View articletitled, Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Journal Articles

Abstract 4182: Bioinformatic analysis identifies polo-like kinase as a therapeutic target in small-cell lung cancer

Free
Gary Wildey, Yanwen Chen, Ian Lent, Lindsay Stetson, John Pink, Jill Barnholtz-Sloan, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4182.
https://doi.org/10.1158/1538-7445.AM2014-4182
Published: 01 October 2014
View articletitled, Abstract 4182: Bioinformatic analysis identifies polo-like kinase as a therapeutic target in small-cell lung cancer
Journal Articles

Abstract 847: PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators.

Free
Snehal Dabir, Yu Liu, Gary Wildey, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 847.
https://doi.org/10.1158/1538-7445.AM2013-847
Published: 15 April 2013
View articletitled, Abstract 847: PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators.
Journal Articles

Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways.

Free
Kriti Mittal, Henry Koon, Paul Elson, Pierre Triozzi, Afshin Dowlati, Ernest Borden, Brian Rini
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 1184.
https://doi.org/10.1158/1538-7445.AM2013-1184
Published: 15 April 2013
View articletitled, Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways.
Journal Articles

Abstract 2249: Induction of PIAS3 by curcumin as a novel treatment strategy in mesothelioma.

Free
Snehal Dabir, Gary Wildey, Afshin Dowlati
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2249.
https://doi.org/10.1158/1538-7445.AM2013-2249
Published: 15 April 2013
View articletitled, Abstract 2249: Induction of PIAS3 by curcumin as a novel treatment strategy in mesothelioma.
Journal Articles

Abstract 1743: Phase 1 clinical trial of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) in combination with Temozolomide (TMZ) in patients with solid tumors

Free
Panos S. Savvides, Yan Xu, Lili Liu, Lisa Rogers, Joseph Bokar, Paula Silverman, Afshin Dowlati, Stanton L. Gerson
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1743.
https://doi.org/10.1158/1538-7445.AM2012-1743
Published: 15 April 2012
View articletitled, Abstract 1743: Phase 1 clinical trial of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) in combination with Temozolomide (TMZ) in patients with solid tumors
Journal Articles

Abstract 753: Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase 1 clinical trial

Free
Panos S. Savvides, Yan Xu, Lili Liu, Lisa Rogers, Smitha Krishnamurthi, Afshin Dowlati, Stanton L. Gerson
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 753.
https://doi.org/10.1158/1538-7445.AM2012-753
Published: 15 April 2012
View articletitled, Abstract 753: Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase 1 clinical trial